Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edelgard Lindhoff-Last

Showing results (21-30 of 112) with videos related to

Pageof 12
Sort By:
Thrombosis and Haemostasis|November 10, 2012
Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditionsHelen Mani, Christian Hesse, Gertrud Stratmann, et al.
Thrombosis and Haemostasis|June 10, 2011
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration timeHelen Mani, Christian Hesse, Gertrud Stratmann, et al.
International Journal of Molecular Sciences|March 29, 2023
The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or VaccinationOlivia Ott, Eva Herrmann, Annabel Schulz, et al.
Journal of Clinical Medicine|August 26, 2022
Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO RegistryAnnabel Schulz, Eva Herrmann, Olivia Ott, et al.
Thrombosis and Haemostasis|June 24, 2004
Safe anticoagulation with danaparoid in pregnancy and lactationMarc Schindewolf, Gerlinde Mosch, Rupert M Bauersachs, et al.
Annals of Medicine|June 11, 2013
Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assaysEdelgard Lindhoff-Last, Jack Ansell, Theodore Spiro, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 5, 2003
Acquired protein C and protein S deficiency in HIV-infected patientsMatthias Erbe, Volker Rickerts, Rupert Martin Bauersachs, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 8, 2008
A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparinFrank Gerdsen, Beate Luxembourg, Florian Langer, et al.
Annals of Hematology|February 28, 2009
Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-upBirgit Linnemann, Stephanie Prochnow, Helen Mani, et al.
Lancet (London, England)|May 31, 2012
Heparin-induced skin lesionsMarc Schindewolf, Edelgard Lindhoff-Last, Ralf J Ludwig, et al.
Pageof 12

Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
Thrombosis and Haemostasis|November 10, 2012
Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditionsHelen Mani, Christian Hesse, Gertrud Stratmann, et al.
Thrombosis and Haemostasis|June 10, 2011
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration timeHelen Mani, Christian Hesse, Gertrud Stratmann, et al.
International Journal of Molecular Sciences|March 29, 2023
The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or VaccinationOlivia Ott, Eva Herrmann, Annabel Schulz, et al.
Journal of Clinical Medicine|August 26, 2022
Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO RegistryAnnabel Schulz, Eva Herrmann, Olivia Ott, et al.
Thrombosis and Haemostasis|June 24, 2004
Safe anticoagulation with danaparoid in pregnancy and lactationMarc Schindewolf, Gerlinde Mosch, Rupert M Bauersachs, et al.
Annals of Medicine|June 11, 2013
Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assaysEdelgard Lindhoff-Last, Jack Ansell, Theodore Spiro, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 5, 2003
Acquired protein C and protein S deficiency in HIV-infected patientsMatthias Erbe, Volker Rickerts, Rupert Martin Bauersachs, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 8, 2008
A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparinFrank Gerdsen, Beate Luxembourg, Florian Langer, et al.
Annals of Hematology|February 28, 2009
Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-upBirgit Linnemann, Stephanie Prochnow, Helen Mani, et al.
Lancet (London, England)|May 31, 2012
Heparin-induced skin lesionsMarc Schindewolf, Edelgard Lindhoff-Last, Ralf J Ludwig, et al.
Pageof 12